Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05267873 · ClinicalTrials.gov registry record
Combining Data Sources to Identify Effect Moderation for Personalized Mental Health
A clinical trial, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- 9,586
- Enrollment target
NCT05267873: Completed study, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT05267873 is a clinical trial that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 9,586 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05267873 has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- 9,586 participants
- Enrollment target
Study Summary
This work will extend and apply methods for modeling heterogeneous treatment effects when multiple studies are available, with a particular focus on the complexities in mental health research. The methods will be illustrated in examples estimating the effects of medical treatments for major depressive disorder (duloxetine and vortioxetine) using 4 randomized controlled trials (available in the Vivli trials resource) and non-experimental data from the Duke University Health System electronic health record and the Johns Hopkins Health System electronic health record systems.
Primary Outcome
Higher score indicates greater severity of major depressive disorder.
Interventions
- DRUG Duloxetine, Vortioxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,586 participants |
| Start Date | 2015-01-01 |
| Est. Completion | 2024-12-01 |
What the finished NCT05267873 record still lists
NCT05267873 is an observational study that tracks outcomes without assigning an intervention. Its 9,586 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Duloxetine, Vortioxetine is the first listed.
NCT05267873 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05267873 about?
NCT05267873 is a clinical study titled "Combining Data Sources to Identify Effect Moderation for Personalized Mental Health". This work will extend and apply methods for modeling heterogeneous treatment effects when multiple studies are available, with a particular focus on the complexities in mental health research. The methods will be illustrated in examples estimating the effects of medical treatments for major depressi...
What is the current status of trial NCT05267873?
This trial is currently completed. The enrollment target is 9,586 participants. The study started on 2015-01-01. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT05267873?
The interventions under investigation include: Duloxetine, Vortioxetine (DRUG).
Who is sponsoring clinical trial NCT05267873?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05080673 · 9,500 participants · NA
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI